Creatine phosphokinase elevation exacerbated by levetiracetam therapy

A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levet...

Descripción completa

Detalles Bibliográficos
Autores principales: Isaacson, Julia E., Choe, Dongwhoon J., Doherty, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308055/
https://www.ncbi.nlm.nih.gov/pubmed/25667904
http://dx.doi.org/10.1016/j.ebcr.2014.09.008
Descripción
Sumario:A 19-year-old muscular male with a history of epilepsy presented following two convulsive events. Levetiracetam (LEV) was given as an additional therapy, resulting in a marked boost in creatine phosphokinase (CPK) that could not easily be explained by renal dysfunction or rhabdomyolysis alone. Levetiracetam discontinuation caused CPK levels to quickly normalize and should be considered in patients with persisting CPK elevations postconvulsive seizure.

Ejemplares similares